Table 2.

Comparison of cefepime plasma and ELF exposures achieved in humans receiving 2 g every 8 h as 4 h infusion versus infected mice receiving cefepime human-simulated regimen subcutaneously

Matrix/regimen	Species	%fT>MIC for an MIC (mg/L) of:							fAUC0–24 (mg·h/L)	fC max (mg/L)	ELF:plasma penetration
		2	4	8	16	32	64	128
Plasma
	Human	100	100	99	73	45	0	0	700.9	52.0
ȃMonotherapy	Mouse	100	100	93	77	35	0	0	656.8	54.0
ȃIn combination with taniborbactam 1.56% HSR	Mouse	100	100	100	97	52	0	0	821.0	60.6
ȃIn combination with taniborbactam 12.5% HSR	Mouse	100	100	98	80	37	0	0	668.2	48.9
ȃIn combination with taniborbactam 100% HSR	Mouse	100	99	95	88	59	3	0	858.4	76.9
ELF
ȃMonotherapy	Mouse	100	100	90	50	0	0	0	428.4	31.0	0.65
ȃIn combination with taniborbactam 1.56% HSR	Mouse	100	100	98	70	14	0	0	516.7	35.8	0.63
ȃIn combination with taniborbactam 12.5% HSR	Mouse	100	100	93	51	2	0	0	406.1	34.2	0.61
ȃIn combination with taniborbactam 100% HSR	Mouse	100	100	95	74	17	0	0	545.2	39.0	0.64

HSR, human-simulated regimen.